Rome, November 23 – The Merck pill against Covid should be taken twice a day for five days and treatment should be started. “as soon as possible” after diagnosis and in any case within 5 days of the first symptoms. These are the indications of the European Medicines Agency for Lagevrio, antiviral based molnupiravir for the treatment of Covid-19, developed by MSD in collaboration with Ridgeback Biotherapeutics, which will be available in capsules.
The drug, according to an opinion released last November by the CHMP, the Commission for Medicinal Products for Human Use of the Community Regulatory Authority, “Not recommended in pregnancy” and breastfeeding “Must be discontinued during treatment and for 4 days after treatment”.
Here is a summary of some of the main contents of the advice for its use Lagevrio (also known as MK 4482) issued by the group of experts of the European Agency. The opinion, according to an Ema note, was issued to support the national authorities of the various Member States who could decide on a possible early use of the medicine before the European marketing authorization, for example in emergencies. and deaths from Covid across the EU.
It is given at a dose of 800 mg twice a day, Lagevrio reduced the risk of hospitalization and death when treatment was started within 5 days of the onset of symptoms. About one month after starting treatment, 7.3% of patients (28 out of 385) received Lagevrio compared with 14.1% (53 of 377) of placebo patients who had been hospitalized or died. none of the patients in the group Lagevrio died compared with eight patients in the placebo group. In terms of safety, the most common side effects reported during treatment and within 14 days of the last dose Lagevrio it was diarrhea, nausea, dizziness and headache, all mild or moderate.